Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones – Collaboration with Astellas on discovery and development of iADCs for up to three targets, includes an upfront payment of $90 million and $422.5...
Sutro Biopharma
310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412
